A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ANX1502 in Normal Healthy Volunteer
Latest Information Update: 30 Dec 2024
At a glance
- Drugs ANX 1502 (Primary)
- Indications Autoimmune disorders; Neurodegenerative disorders
- Focus Adverse reactions; First in man
- Sponsors Annexon
- 14 Oct 2024 Planned number of patients changed from 84 to 141.
- 14 Oct 2024 Planned End Date changed from 30 Jun 2023 to 1 Nov 2024.
- 14 Oct 2024 Planned primary completion date changed from 30 Jun 2023 to 1 Nov 2024.